Transient receptor potential (TRP) channels and purinergic receptors are expressed in neural and non-neural elements of the lower urinary tract (LUT) and are thought to contribute to physiological and pathological function. Targeting TRP channels and purinergic receptors in the LUT could affect mechanosensation, chemosensation, pain perception, and excitability of bladder sensory nerves to modulate the afferent limb of the micturition reflex and affect the overall function of the urinary bladder.
.
The mucosal layer consists of transitional epithelial cells that line the lumen of the bladder and a lamina propria beneath the basement membrane of the epithelial cells. The transitional epithelial cells, termed the urothelium, function not only as an impermeable, nonadherent barrier, but also as a sensory component that is capable of responding to multiple stimuli 2 . The lamina propria of the urinary bladder contains interstitial cells of Cajal (ICC), vasculature, and nerve terminals that have all been proposed to integrate epithelial and smooth muscle input to maintain normal bladder function 3 . Cells similar to ICC, as observed in the gastrointestinal tract, have been found in the urinary bladder of various species (including mouse, guinea pig, rabbit, and human); however, whether species differences exist is not known, their specific functions have not yet been determined, and much controversy currently exists regarding the exact function of these cells 4 . The muscular layer is organized into three smooth-muscle compartments that are collectively termed the detrusor. The detrusor smooth muscle is structurally different from that of the urethral smooth muscle in that it consists of inner and outer longitudinal layers and a middle circular layer 5 . The serosa surrounds the superior and lateral external surfaces of the bladder wall, whereas the retroperitoneal bladder wall is surrounded by loose connective tissue termed adventitia 1 . The urethra functions as the outlet from the urinary bladder to the external world and its tissue wall is organized into mucosal, muscular, and adventitial layers (FIG. 1) . The cells lining most of the urethral mucosa are nonkeratinized, stratified squamous epithelial cells as the urethra does not have to accommodate the mechanical forces experienced by the urinary bladder 6 . In men, the smooth muscle layer of the urethra is arranged into inner longitudinal and outer circular layers and is termed the internal urethral sphincter 7 . However, in women, the smooth muscle layers do not seem to establish an internal sphincter 7 . The striated muscle layer surrounding the proximal urethra is termed the external urethral sphincter and provides voluntary control over bladder filling.
Neural control of micturition
The storage and elimination of urine are important and necessary in daily life and involve intricate neural signalling pathways requiring coordination of the urinary bladder and urethra 5, 8 (FIG. 1) . The micturition reflex is often referred to as a spinobulbospinal system as information travels from the spinal cord to the brainstem and back to the spinal cord to relay information regarding urinary bladder filling 9 . During the emptying phase of the micturition cycle, parasympathetic nerve cotransmission involving ATP and acetyl choline acting on smooth muscle P2X purinoceptor 1 (P2X 1 ) and muscarinic receptors (M 2 and M 3 ) mediates urinary bladder contraction. During the storage phase of the micturition cycle, the sympathetic nervous system inhibits detrusor smooth muscle contraction, enabling the bladder to relax and increase in size. In addition, the urethral sphincters contract in response to background stimulation from the sympathetic and somatic nervous systems 9 . The switch to the emptying phase is triggered by tension in the bladder that stimulates stretch receptors (which are slowly adapting mechanoreceptors) within the bladder 9 . These receptors activate Aδ and C fibres (sensory afferent nerves) that convey information about bladder filling and noxious stimuli, respectively, from the bladder neck and urethra to sacral spinal cord levels S2-S4 via the pelvic, pudendal, and hypogastric nerves 10 . Low-level afferent nerve discharge is present throughout bladder filling. During bladder filling, as hydrostatic pressure rises, thinly myelinated Aδ afferent fibres of the hypogastric and pelvic nerves increase their activity 10 (FIG. 2) . Bladder afferent nerves that terminate peripherally in the urinary bladder might also signal through unmyelinated C fibres that respond to nociceptive stimuli (such as chemicals, inflammation, and elevated intravesical pressures). C fibres are quiescent (silent C fibres) during normal bladder filling, but their activation might contribute to the development of LUT symptoms and pathological disorders of the urinary bladder 10 . The sensation of bladder fullness is experienced in humans with intravesical pressures of 5-15 mmHg 11 . On passing this tension threshold, bladder afferent discharge increases to stimulate micturition reflexes (FIG. 2) . Urinary urgency occurs in humans when intravesical pressures reach 20-25 mmHg and, if not relieved, pain and/or discomfort occurs when pressures exceed 30 mmHg 11 . Aδ and C fibres from the urinary bladder enter the spinal cord through the Lissauer tract and synapse in laminae (I, V, VII, and X), which contain parasympathetic preganglionic neurons and neurons that project to the periaqueductal grey (PAG) 9 . Signals then travel from the PAG to the pontine micturition centre (PMC) and back to the lumbosacral spinal cord to synapse on preganglionic sympathetic and parasympathetic neurons 9 . Multiple higher brain centres project to the PAG including the hypothalamus, preoptic region, central nucleus of the amygdala, bed nucleus of the stria terminalis, and prefrontal cortex. During the filling phase, signals from these higher brain centres inhibit the PAG reducing excitation of the PMC, which prevents inappro priate voiding or incontinence 10 . However, during the voiding phase, activation of the PMC suppresses preganglionic sympathetic control (which releases the contraction of the sphincter and removes the inhibition of the detrusor) and enables the parasympathetic system to stimulate detrusor smooth muscle contraction and the expulsion of urine.
The sensory component of the urothelium The urothelium has previously been considered a passive barrier; however, a large and growing body of literature now demonstrates that it has additional and important physiological roles 12, 13 . Current evidence indicates that the urothelium has specialized sensory and transduction or signalling properties that enable it to respond to chemical or mechanical stimuli (such as changes in bladder pressure or tension, and tonicity of urine) 12, 13 , as well as acting as a functional barrier against urine solutes. The distribution of anatomical components (FIG. 1) suggests that reciprocal communication is possible between urothelial cells that are [15] [16] [17] . The sensory inputs and outputs of the urothelium that result in receptor-mediated and channel-mediated events at the urothelium and subsequent release or secretion of chemical mediators have been described using the term 'urothelial-associated sensory web' (REF. 12 ).
Anatomical proximity of nerve fibres to the urothelium
Findings of a 2002 study established that both sensory afferent and autonomic efferent nerves are located in a suburothelial plexus in close proximity to, and extending into the urothelium 18 (FIG. 3) . Adrenergic (tyrosine hydroxylase positive) and cholinergic (choline acetyltransferase positive) nerves have also been observed in close proximity to the urothelium 19 . Additionally, the suburothelial plexus exhibits immunoreactivity for neuropeptides (such as calcitonin gene-related peptide, substance P, corticotropin-releasing factor (CRF)), and receptors such as P2X 3 and P2X 2/3 receptors and transient receptor potential vanilloid receptor 1 (TRPV1) 2, 20, 21 (FIG. 3) . The sensory function of these nerve fibres was indicated by intravesical administration of the ultrapotent C fibre neurotoxin resiniferatoxin, which reduced the density of TRPV1 and P2X 3 immunoreactive suburothelial nerves in humans with neurogenic detrusor overactivity 16, 22, 23 . The neural pathways that control lower urinary tract function maintain a reciprocal relationship between the urinary bladder and the urethral outlet. Storage reflexes are activated during bladder filling and are organized primarily in the spinal cord, whereas voiding is mediated by reflex mechanisms that are organized in the brain. During bladder filling and storage, the parasympathetic innervation of the detrusor is inhibited and the smooth and striated parts of the urethral sphincter are activated, preventing involuntary bladder emptying. During bladder filling the parasympathetic efferent pathway to the bladder, including a population of CNS (for example pontine micturition centre) neurons, is turned off. As bladder filling continues and a critical level of bladder distension is achieved, the afferent activity from mechanoreceptors in the bladder switches the pathway to the elimination mode. During elimination (voiding), parasympathetic activity is activated resulting in urinary bladder contraction, whereas sympathetic activity and somatomotor activity is withdrawn. b | Anatomical components of the urinary bladder wall. Numerous receptors (including purinergic, adrenergic, cholinergic, neurotrophin, and neuropeptide) and ion channels (transient receptor potential channels) are expressed by the anatomical components of the urinary bladder wall including the urothelium, bladder sensory nerves, interstitial cells of Cajal (ICC), and detrusor smooth muscle. and ASIC3) 29 , neurotrophin receptors (p75 NTR and tropo myo sin receptor kinases A and B) [30] [31] [32] [33] , CRF receptors 1 and 2 (REF. 21 ), transient receptor potential (TRP) (including TRPV1, TRPV2, TRPV4, TRPM7, TRPM8, TRPA1) channels 2, 24, [34] [35] [36] (TABLE 1) , neuropeptide receptors (such as pituitary adenylyl cyclase-activating polypeptide (PACAP) type I receptor and vasoactive intestinal polypeptide (VIP) receptor 2) 24, 25, 37 , and chemokine receptors (such as CXCR4, CX3CR1) 38 . The expression of these receptors and ion channels means that the urothelium can respond to diverse stimuli from many sources including: stretching and distension during bladder filling 2, 24, [34] [35] [36] , soluble factors such as nerve growth factor (NGF) 24 , neuroactive compounds such as PACAP 25 , VIP25 , CRF 21 , acetylcholine 2 , ATP or noradrenaline 2 (which are released from nerves and inflammatory cells), chemokines (including CXCL1, CXCL12, CX3CL1, CCL2), which are released from inflammatory cells [38] [39] [40] , and changes in pH resulting from inflammation 2, 41 .
Urothelial expression of receptors and ion channels

Urothelial secretion of transmitters and mediators
A variety of signalling molecules (such as neurotrophins, neuropeptides, ATP, acetylcholine, prostaglandins, prostacyclin, nitric oxide and cytokines) are secreted by the urothelium 2, 24, 36, 42 and it is able to communicate, possibly in a reciprocal manner, with other cell types including bladder nerves, smooth muscle cells, interstitial cells and inflammatory cells 2, 27 . ATP seems to be the main messenger released from urothelial cells during purinergic mechanosensory transduction that acts on P2X 3 receptors on sensory nerves to generate signals that indicate bladder fullness, and pain 17, 43 (FIG. 3) .
In this Review, we discuss examples of receptors that are expressed in the urothelium (FIGS1,3; TABLE 1), their responses on activation and their regulation in experimental models and human studies of bladder dysfunction, where appropriate. This Review will highlight several principal components (including TRP channels and purinergic receptors and receptor signalling) that might underlie the afferent limb of the micturition reflex and to describe how their modulation might influence the sensory processing of bladder filling (FIGS 1,3;
TABLE 1).
Transient receptor potential channels TRP channels are a superfamily of nonspecific cation channels that are generally, but variably, permeable to Ca 2+ (REFS 44, 45) and might act as sensors of stretch and/or chemical irritation in the LUT 35, [46] [47] [48] . More than 50 TRP channels have been described in species from yeast to human and 28 have been discovered so far in mammals 49 . The TRP channel superfamily consists of seven subfamilies: TRPC (canonical), TRPM (melastatin), TRPV (vanilloid), TRPA (ankyrin), TRPP (polycystin), TRPML (mucolipin), and TRPN (no mechanopotential).
TRP channels in the lower urinary tract
Multiple TRP channels from different subfamilies, including TRPV1, TRPV2, TRPV4, TRPM7, TRPM8, and TRPA1 are expressed in the urinary bladder, have specific tissue distributions in the LUT, are activated by numerous exogenous and endogenous mediators 34, 35, 50 (FIG . 3; TABLE 1) , and might have functional roles in the micturition reflex 46, 51 . Many of these channels are also implicated in bladder disorders including overactive bladder (OAB) and interstitial cystitis/bladder pain syndrome (IC/BPS) 49, 52 . TRPV1 is the most widely studied TRP channel with regards to its role in urinary bladder function, but other studies also suggest the involvement of TRPV4 in both normal urinary bladder function and dysfunction 46 . Other TRP channels have also been observed in the LUT (TABLE 1) .
Members of the ankyrin, vanilloid, and canonical families of TRP channels have distributions and functions specific to the LUT (TABLE 1) . For example, TRPA1 is expressed in unmyelinated C fibres throughout the urinary bladder 53 and colocalizes with TRPV1-containing peptidergic nerve fibres 54 . TRPA1 transcripts, detected in the urothelium, are upregulated in the bladder mucosa of humans with bladder outlet obstruction 55 ; however, the results of functional experiments in mice suggest that TRPA1 does not contribute to mechanosensation in the urothelium 56 . TRPA1 does seem to have a role in the afferent limb of the micturition reflex as intravesical TRPA1 agonists (such as allyl isothiocyanate and cinnamaldehyde) have been demonstrated to decrease micturition-threshold pressure, intercontraction intervals, and voided volume and increase micturition frequency in rats 53, 57 . These agonists might act at the level of bladder afferent nerves to contract the detrusor smooth muscle and alter bladder function 58 . TRPV2 is expressed in superficial cells of the urothelium 56, 59 , detrusor smooth muscle cells 59 , and nerve fibres within the suburothelium 59 . The TRPV2 agonist tetrahydrocannabinol (THC) has been shown to reliably induce Ca 2+ influx into ATP-primed urothelial cells, suggesting that ATP might facilitate TRPV2 trafficking to the plasma membrane 56 . Patch clamp studies also demonstrated THC-induced currents in urothelial cells, supporting the functional expression of TRPV2 in the urinary bladder 56 . TRPV2 knockout mice exhibit decreased embryonic weight and perinatal viability with surviving adult mice still demonstrating reduced body weight 60 . Behavioural assays and neurophysiological studies failed to demonstrate the necessity for TRPV2 in the detection of noxious heat or mechanical stimulation under normal or pathological conditions 60 . Additional work is needed to determine the role of TRPV2 in bladder sensation, as this receptor does not seem to be essential for heat or mechanical nociception or hypersensitivity but is important for perinatal survival 60 .
TRPCs are calcium-permeable, nonselective cationic channels implicated in neuronal cell growth, remodelling, axon guidance, and growth-cone signalling. Cyclophosphamide (CYP)-induced cystitis has been shown to increase TRPC1 and TRPC4 expression in bladder sensory neurons and also increase sprouting of bladder sensory neurons in bladder mucosa. CYPtreated Trpc1/c4 −/− mice failed to exhibit increased bladder sensory neuron sprouting and failed to demonstrate increased voiding frequency with CYP treatment 61 . Members of the TRPM channel family also have diverse functions in the LUT (TABLE 1) . TRPM8 is expressed in the urothelium 62 and in Aδ fibres and C fibres throughout the suburothelium of the urinary bladder 54, 55 . Similar to other TRP channels, the functional expression of TRPM8 in the urothelium is unclear as pharmacological manipulation experiments suggest little to no functional response to agonists in urothelial cells 56 . However, TRPM8 is functionally involved in the micturition reflex through bladder afferent nerve activation 63 , a cold-induced urgency reflex 64 and a bladder-cooling reflex that is observed in patients with supraspinal neuronal lesions 65 . TRPM8-containing C fibres might underlie these reflexes in humans owing to the absence of urothelial cell responses to TRPM8 agonists during Ca 2+ imaging or patch-clamp experiments 56 and because C fibre density is increased in pathological bladder conditions (such as spinal cord injury) 55 . Additionally, C-fibre activation via TRPM8 seems to contribute to the cooling reflex in guinea pigs 66 , whereas, activation of Aδ fibres might underlie this reflex in rats 67 . TRPM2 is a nonselective calcium-permeable cation channel, activated by free intracellular adenosine diphosphate ribose in response to oxidative stress and cell-death signals. TRPM2 mRNA expression is increased in human bladder samples from patients with non-ulcerative interstitial . TRPM2 overexpression resulted in apoptosis of T24 bladder cancer cells, suggesting that it is a potential therapeutic target for bladder carcinogenesis 69 . TRPM7 is expressed in the cytoplasm of urothelial cells 51 and its expression was proven to be higher in a cancer cell line generated from bladder than in normal urothelial cells. TRPM7 expression in bladder cancer cells might act as a negative regulator of cell proliferation and prevent excess mechanical stress enabling cells to be maintained in a healthier state 70 .
TRPV1 and TRPV4 expression in the lower urinary tract TRPV1 has been detected in all human genitourinary tract tissues and most LUT structures in mice 46, 52 , but its expression pattern has recently been questioned, particularly in the urothelium. TRPV1 expression has been observed in neuronal and non-neuronal human and rat LUT tissues including the urothelium, suburothelial nerve plexus, detrusor smooth muscle, ICC, and sensory afferent neurons 46, 52 (FIG. 3; TABLE 1 ). The expression and function of TRPV1 channels in the bladder, specifically in the urothelium, is controversial 34, 46 . Birder et al. 18 described ATP release from cultured rat urothelial cells on application of the TRPV1 agonist, capsaicin, which was blocked by co-administration of the TRPV1 antagonist, capsazepine. Furthermore, capsaicin activation of TRPV1 induced increased intracellular calcium and inward cation currents in cultured urothelial cells from rats and humans 71, 72 . The expression of TRPV1 in the urothelium has been reported using several methods including quantitative PCR, immunohistochemistry, and western blotting in different species 71, 73, 74 . However, the specificity of TRPV1 antibodies has been questioned and absence of appropriate controls (such as use of knockout animals) has been criticized 75 . Considerable support exists for TRPV1 expression in small diameter bladder afferent fibres in close proximity to the urothelium and in bladder sensory neurons in the dorsal root ganglia (DRG) but not by the urothelial cells 51, 76, 77 . Moreover, two independent groups did not record TrpV1-induced calcium currents in cultured urothelial cells from guinea pigs and mice 56, 78 . In 2011, Cavanaugh et al. 79 designed a Trpv1-reporter mouse that enables the expression of a nuclear β-galactosidase (lacZ) and the placental alkaline phosphatase with the putative TrpV1 expression pattern without disturbing TrpV1 function. These investigators reported that TrpV1 is primarily restricted to nociceptors in the DRG, with minimal expression in a few brain regions, and no TRPV1 expression in urinary bladder.
The intravesical administration of the TRPV1 activators, capsaicin or resiniferatoxin (TABLE 1) , which desensi tize afferent neurons, has been introduced into clinical practice for treatment of neurogenic detrusor overactivity (NDO) resulting in symptom improvement and major adverse effects 34, 46, 80 , emphasizing the need for the identification of additional targets (such as TRPV, TRPM, and TRPA channels and purinergic receptors and/or channels) (TABLE 1) that could result in improved urinary bladder function 81 . Intravesical instillation of capsaicin in patients with NDO reduced urinary frequency and urge incontinence and increased bladder capacity; however, treatment resulted in severe side effects (including bladder pain, suprapubic burning, bladder overactivity, and hot flashes) 34 ,46,80 making treatment poorly tolerated. Findings from two studies 82, 83 have demonstrated that interaction between TRPV1 and anoctamin-1 (ANO1), a calcium-activated chloride channel, is a pain-enhancing mechanism in sensory neurons, suggesting that blockade of TRPV1-ANO1 interactions might be a novel analgesic target. TRPV1 is the most widely studied TRP channel regarding its role in urinary bladder function, but other studies also suggest the involvement of TRPV4 in both normal bladder function and dysfunction 46 . The expression of TRPV4 has also been established in different tissues and systems throughout the body including the central nervous system (CNS) and peripheral nervous system (PNS). Within the urinary bladder, TRPV4 was first demonstrated to be expressed in basal and intermediate urothelial cells 84 and expression in the urothelium has been subsequently confirmed by other studies 51, 72, 76, 85, 86 . The functional expression of TRPV4 in urothelial cells has been established following measurements of ionic currents and Ca 2+ signalling events induced by agonists (such as 4α-phorbol 12,13-didecanoate (4α-PDD) or GSK1016790A) or stretch 72, 78, 85 . TRPV4 is also expressed in the detrusor smooth muscle; however, transcript levels were found to be approximately 20-fold to 36-fold higher in the urothelium than the detrusor smooth muscle 78, 87 perhaps suggesting a more prominent role in urothelial function. TRPV4 expression has also been observed in the DRG neurons innervating viscera 76, [88] [89] [90] but functional evidence is lacking 88 .
TRPV and bladder function
Pharmacological approaches and the use of Trpv1-knockout mice have started to demonstrate the roles of TrpV1 in the micturition reflex 52 . Investigation of bladder function of Trpv1-knockout mice has revealed a higher frequency of nonvoiding bladder contractions than in wild-type mice, as well as a reduction in reflex voiding during bladder filling 18 . Additionally, the Trpv1-knockout mouse model does not develop bladder overactivity during acute bladder inflammation, suggesting that TrpV1 is involved in bladder hyperreflexia in response to inflammation 52 .
CYP-induced cystitis results in significantly increased
TrpV1 and TrpV4 expression 4 h and 48 h after injection (acute cystitis), and in models of chronic cystitis (P = 0.01); however, Trpv1 transcript expression was significantly reduced in urothelial and suburothelial tissues from rats that underwent 4 h and 48 h acute cystitis but significantly increased in detrusor tissue from rats with chronic CYP-induced cystitis (P <0.01) 36 . The lack of correlation between Trpv1 transcript and protein expression might reflect changes in post-transcriptional and post-translational mechanisms including increased protein stability 36 . The increased Trpv1 expression demonstrated with CYP-induced cystitis is consistent with the hypothesis that TRPV1 contributes to bladder hyperreflexia in response to inflammation 52 .
The deletion of Trpv4 in mice has also helped to elucidate its physiological role in diverse functions, including the micturition reflex. Authors of studies have reported mild phenotypic effects in Trpv4-knockout mice such as abnormal responses to both osmotic and somatosensory mechanical stimuli where hyperalgesia is absent, deficits in osmotic homeostasis leading to cell-size changes and functional abnormalities, increased blood osmolarity causing dehydration, alkalosis, or acidosis, increased bone mass, ageing-related hearing impairment, and reduced water consumption, all potentially being fatal 45, 52 . Urodynamic measurements showed that Trpv4-knockout mice have abnormal urine voiding patterns characterized by a decreased frequency of voiding contractions and increased frequency of nonvoiding contractions, longer intermicturition intervals and increased total urine volume per void 45, 84, 85 . Pharmacological manipulation has also been an effective tool to help define the role or roles of TRPV4 in bladder function. Administration of the TRPV4 agonist 4α-PDD to conscious rats resulted in an increase in the amplitude of reflex bladder contractions during cystometry 85 . GSK1016790A, a highly selective TRPV4 agonist that is ~300-fold more potent than 4α-PDD, similarly induced bladder hyperactivity in vivo in mice 87 and rats 91 . Systemic administration of the selective and potent TRPV4 antagonist HC-067047 decreased voiding frequency and increased bladder capacity in mice and rats following CYP-induced cystitis 45 .
TRPV1, TRPV4 and purinergic signalling
Studies suggest that TRPV1 and TRPV4 regulate ATP release from the urothelium that occurs in response to bladder distension 18, 84 . Sensory neurons terminating in the bladder wall were originally thought to initiate the micturition reflex; however, the urothelium has now been proven to participate in the sensory response to bladder filling 76, 92 . Mechanical stretch evokes the release of ATP from urothelial cells and mechanosensitive contributions of TRPV4 and possibly TRPV1 channels present on the urothelial cell surface might contribute to this process (FIG. 1) . Functional evidence in support of TRPV4 involvement in the release of ATP was demonstrated with the administration of 4α-PDD to cultured urothelial cells, which subsequently released ATP, an effect that was blocked by ruthenium red, a pan inhibitor of TRP channels 85 . Similarly, capsaicin evoked ATP release from cultured urothelial cells 18 and bladder mucosal strips 93 that was abolished with the coadministration of the TRPV1 antagonist, capsazepine, suggesting a role of TRPV1 in ATP release. The influence of TRPV1 and TRPV4 on ATP release has also been confirmed in knockout mice. ATP release is suppressed in response to a hypotonic stimulus 18 or mechanical stretch 86 of cultured urothelial cells from Trpv1-knockout and Trpv4-knockout mice. The importance of transmembrane Ca 2+ flux through TRPV channels is still disputed 86, 94 , studies provide support for TRPV-mediated sensory transduction at the level of the urothelium that results in ATP release 86, 94 . Subsequent P2X receptor signalling on bladder sensory neurons (among other cell types) might contribute to the afferent limb of the micturition reflex.
ATP and purinergic receptors
The urothelium releases neuroactive transmitters, in particular ATP, from its apical and basolateral surfaces in response to physical and chemical stimuli 2, 95 . ATP and other nucleosides (including ADP, UTP, and UDP) that are derived from the urothelium can be released through several mechanisms that include transporters, ion channels, or vesicular exocytosis 96, 97 (FIG. 3) .
Extracellular ATP that is not degraded by ectonucleotidases or exonucleo tidases is then able to stimulate autocrine or paracrine pathways that might aid in sensory transduction to the CNS 98 . The transduction pathways within the urinary bladder are affected by receptor subtype expression and their proximity to the urothelium. The tissues and cell types that might contribute to purinergic or pyrimidinergic signalling include the urothelium 98, 99 , ICC 27 , smooth muscle cells 100,101 and suburothelial nerve fibres 2, 24 (FIG. 3) .
Nucleosides and their metabolites seem to have an intricate role in ATP release and purinergic receptor signalling in the urothelium. More specifically, ADP has been demonstrated to evoke ATP release from the urothelium, whereas adenosine inhibits ATP release via A1 receptors 98, 102 . The urothelium also expresses diverse purine and pyrimidine receptor subtypes enabling distinct signal transduction [103] [104] [105] [106] . The activation of P2Y, but not P2X, receptors on the urothelium causes ATP release, suggesting urothelial P2Y receptors might contribute to purinergic neurotransmission 103, 107 . However, P2X 2 and P2X 3 receptor expression is altered in urothelium from patients with interstitial cystitis indicating that P2X receptors are involved in urinary bladder sensory transduction in bladder injury or disease 105 . ICC in the lamina propria (ICC-LP) of the urinary bladder also express P2X 3 , P2Y 2 , P2Y 4 , and P2Y 6 receptors and are proposed to form a functional syncytium with smooth muscle cells 108, 109 . In response to ATP, ICC-LP generate P2Y-dependent intracellular calcium transients followed by inward currents 109 . These ATP-generated transients could then propagate to smooth muscle cells via gap junctions to alter contractility 110 . The mechanism coupling ICC-LP to sensory activity is not yet known, but the localization of ICC-LP and their responsiveness to ATP suggest they have a regulatory role in the afferent limb of the micturition reflex 110 . In addition to the functional syncytium with ICC-LP, urinary bladder smooth muscle cells express P2X 1 to P2X 6 receptors and P2Y receptors 111 . P2X 1 receptors are the predominant receptors in purinergic cotransmission mediating bladder contractility 112 . P2Y 6 receptors have also been demonstrated to augment P2X-mediated bladder contraction, suggesting that extracellular UDP and P2Y 6 -receptor activation might have a role in pathological bladder conditions involving smooth muscle tone 113 . Bladder afferent nerves that terminate throughout the layers of the urinary bladder have been shown to express P2X 1-7 , P2Y 1 , P2Y 2 , and P2Y 4 receptors [114] [115] [116] . The proximity of afferent nerve terminals to the basal layer of the urothelium indicates that sensory nerves have a role in purinergic sensory transduction, but the data are not yet conclusive. Studies have established the functional contributions of P2X 2 and P2X 3 receptors to the afferent limb of the micturition reflex 117 . P2X 3 -receptor-mediated mechanisms contribute to mechanosensory transduction in the urinary bladder because intravesical-α,β-methylene-ATP, a P2X 3 agonist, potentiates both low-threshold, non-nociceptive fibres and high-threshold, nociceptive fibres 118 . Furthermore, mice lacking P2X 2 or P2X 2/3 receptor subunits exhibit decreased urinary bladder reflexes and decreased pelvic afferent nerve activity in response to bladder distention 119 . The functional contributions of P2Y 2 receptors to bladder sensory neuron sensitization have also been demonstrated 120 . P2Y 2 receptor activation is able to facilitate P2X 2 -evoked currents through G-proteincoupled mechanisms, whereas the facilitation of P2X 3 -evoked currents was independent of G-protein-coupled mechanisms 120 . These results suggest that UTP might prime P2X receptor signalling to contribute to neuron hyperexcitability in pathological bladder conditions 120 . In summary, purinergic signalling through P2X receptors contributes to mechanosensory transduction within bladder afferent nerves and contractility within detrusor smooth muscle cells, whereas, P2Y receptors contribute to altered ATP release from the urothelium, calcium transients in ICC-LP, and the sensitization of P2X receptors in detrusor smooth muscle cells and afferent nerve terminals. The variety of cell types involved in purinergic and pyrimidinergic neurotransmission in the urinary bladder suggests a fundamental role in the sensory processing of micturition function making purinergic and pyrimidinergic receptors potential targets to improve voiding dysfunction.
Roles in urinary bladder dysfunction TRPV1 and TRPV4 channels Studies of TRP channels (such as TRPA1, TRPV1, and TRPV4) in the LUT have suggested functional roles in symptoms of OAB 46 , and IC/BPS 49, 52 . In particular, TRPV1 and TRPV4 exhibit plasticity in LUT expression in patients with NDO, OAB, and IC/BPS. Patients with NDO were found to have increased TRPV1 immunoreactivity in suburothelial nerve fibres and basal cell layers of urothelium compared with controls 121 . Localized treatment with intravesical instillation of capsaicin improved symptoms in 84% of these patients, but side effects, including suprapubic burning, urgency, and hot flashes, lasted for 2 weeks after treatment 80 . An increase in TRPV1 transcript levels in trigonal mucosa is also observed in patients with OAB 122 . In addition, patients with IC/BPS have an increase in the numbers of suburothelial TRPV1-immunoreactive nerve fibres 49 . Intravesical capsaicin treatment significantly (P <0.01) improved frequency and nocturia symptoms in these patients, but not urgency or pain 123 . Some studies also suggest that alterations to TRPV4 expression after stress might contribute to urinary bladder dysfunction. Individuals with IC/BPS or OAB exhibit symptom exacerbation (such as urinary frequency) during times of stress [124] [125] [126] [127] . Repeated variate stress (RVS) 128, 129 in rats produces urinary bladder dysfunction characterized by decreased bladder capacity, decreased void volume and increased voiding frequency 130 . In addition to urodynamic changes following RVS exposure, TrpV4 expression in the urothelium also increased. The intravesical administration of the TRPV4 antagonist HC067047 improved bladder capacity and voiding frequency, suggesting TRPV4 might contribute to bladder dysfunction following RVS 130 . Systemic administration of HC067047 also increased bladder capacity and decreased voiding frequency in mice with CYP-induced cystitis, suggesting that TrpV4 might have a fundamental role in bladder function following injury 45 . Stress is also known to potentiate the immune response, and RVS increased inflammatory mediators in the urinary bladder including NGF 130 . The role of NGF in the inflammatory milieu of the urinary bladder is well established, and NGF has also been suggested as a potential biomarker for IC/BPS 131, 132 . We have shown previously that urinary-bladder-derived NGF modulates several TRP channels, including TRPV4 (REFS 36,89); therefore, NGF in the urinary bladder after RVS might contribute to increased TRPV4 expression, but future studies are necessary to address this possibility.
Purinergic receptor expression and signalling
Increased levels of urinary ATP have been demonstrated in patients with interstitial cystitis 133 , OAB 134 , and other functional disorders of the urinary bladder 95 . Primary bladder urothelial cells taken from these patients also exhibit increased ATP release in response to mechanical stretch 133 , hypotonic stress 135 , or electrical field stimulation 136 . In addition to increased urothelial-derived ATP release, changes in P2X receptor subtype expression within various bladder tissues have also been demonstrated in patients with interstitial cystitis (P2X 2 and P2X 3 ) 106 , detrusor instability (P2X 2 ) 137 or bladder outlet obstruction (P2X 1 ) 138 . The established role, or roles of purinergic signalling in bladder sensation suggest that these neurochemical alterations might contribute to the development of LUT symptoms in these patients. Thus, an alternative therapeutic approach to improve bladder function might be to target purinergic neurotransmission within sensory components of the micturition reflex 139 .
Targeting receptors and/or channels
Determining the distribution and function of purinergic receptors or channels and TRP channels in the LUT (TABLE 1) in preclinical studies has the potential to produce safe and effective treatments for sensory voiding disorders. Based on the distribution and function of purinergic receptors and TRP channels in urothelial cells and bladder sensory nerves (TABLE 1) , targeting these receptors and channels could alter mechanosensation (such as urgency), chemosensation and pain perception (such as pain that is attributed to the urinary bladder), and/or the excitability of bladder sensory nerves, therefore, modulating the afferent limb of the mictur ition reflex to the CNS and the overall function of the urinary bladder. Clinical studies are determining the risks and benefits of purinergic receptor and TRP channel antagonists in patients with IC/BPS. For example, results from a phase II clinical trial (NCT01569438) 140 with the selective, non-narcotic, and orally-administered P2X 3 receptor antagonist AF-219 showed a significant (P = 0.034) reduction in urinary urgency and a positive trend in the improvement of pain in patients with IC/BPS 141 . The distribution of the P2X 3 receptor is restricted to sensory nerves, including bladder sensory nerves (TABLE 1) , making it an ideal target for affecting bladder sensory nerve excitability.
TRPV1 has been considered a promising target in IC/BPS based on the function of TRPV1 in the LUT and the benefits of intravesical vanilloids in NDO 81 . However, intravesical capsaicin and its ultrapotent analogue RTX failed to improve pain scores or symptoms in patients with severe pelvic pain or interstitial cystitis 124, 142 . By contrast, hydrodistension combined with intravesical RTX significantly reduced pain at 1 month (P = 0.022) and 3 months (P = 0.041) follow-up duration in patients with IC/BPS 143 . Disappointing results with TRPV1 agonists have resulted in the pursuit of TRPV1 antagonists for clinical development. Unfortunately, use of TRPV1 antagonists (such as AMG517 and XEND0501) produced marked and persistent hyperthermia resulting in early termination of clinical trials 44, 144 . Intravesical administration could circumvent systemic adverse effects but its effects on pain and bladder dysfunction in IC/BPS patients need to be determined. The function of another member of the TRPV family, TRPV4, in the LUT (TABLE 1) in preclinical studies also suggests that TRPV4 antagonists could be an effective treatment for LUT storage disorders; however, no clinical studies have been reported. Preclinical studies with HC067047, a selective antagonist of TRPV4, have demonstrated significant (P ≤0.01) improvement in urinary bladder function (such as reduced urinary frequency) in rodents treated with CYP-induced or RVS-induced bladder dysfunction 45, 145 . Similarly, TRPA1 antagonists need clinical validation in LUT dysfunction but preclinical studies are suggestive of a clinical benefit. For example, in CYP-induced cystitis in mice, the TRPA1 antagonist HC030031 reduced urinary bladder hyperalgesia as demonstrated by visceromotor reflexes quantified by abdominal muscle electromyography 146 . TRPM8 might also be a target, as preclinical studies suggest that TRPM8 antagonists reduce urinary frequency 147, 148 , but they have not advanced to clinical trials. Additional clinical evaluation of purinergic-receptor, purinergicchannel, and TRP-channel antagonists is necessary to determine whether these targets can be effective and safe treatments for sensory voiding disorders.
Conclusions
Urinary bladder function is often taken for granted and given little thought, but attention is quickly redirected when neural injury, disease, or psychogenic stress disrupts this function. Normal urinary bladder reflex function as well as how the micturition reflex is affected by pathology is not yet completely understood, and much is still to be learned. For example, the identity of the sensory transducer at the level of the urothelium that responds to urinary bladder distension is a critical first step in the micturition reflex and is not known. That activation of the urothelium can result in the release of chemical mediators including ATP is better understood, although studies focusing on ATP release mechanisms from the urothelium are less well understood. The micturition reflex is altered with bladder pathology and numerous changes to the urothelium have been documented. Changes in the urothelial cell expression of channels and receptors including TRP and purinergic channels and receptors are observed in IC/BPS, OAB, NDO, and stress. Intensive research efforts are underway focused on identifying urothelial receptors and/or channels that can be targeted by pharmacologi cal tools to improve urinary bladder function. Such a strategy requires a clearer understanding of the identity and function of urothelial TRP channels and ATP release mechanisms in normal and pathological LUT physiology.
